Breaking News Headlines Today | Ground News

See every side of every news story

Deutsches Ärzteblatt image

News from Deutsches Ärzteblatt

Ground News rates Deutsches Ärzteblatt’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Deutsches Ärzteblatt’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Deutsches Ärzteblatt

Where is Deutsches Ärzteblatt located?Deutsches Ärzteblatt's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Deutsches Ärzteblatt News

Four out of every 10 cancer cases are preventable: WHO

Four out of every 10 cancer cases are preventable: WHO

48% Center coverage: 23 sources

PARIS: Nearly four out of every 10 cancer cases could be prevented if people avoided a range of risk factors, including smoking, drinking, air pollution and certain infections, the World Health Organization said on Tuesday (Feb 3).New research published on the eve of World Cancer Day estimated that 38 per cen See the Story

Moms who breastfeed less likely to suffer depression or anxiety

Manassas · Manassas

Moms who breastfeed less likely to suffer depression or anxiety

42% Center coverage: 12 sources

Previous research has shown that breastfeeding reduces the risk of postnatal depression and anxiety.See the Story

Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)

Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)

80% Center coverage: 5 sources

Novo Nordisk A/S (NYSE:NVO) on Monday shared headline results from the REIMAGINE 2 phase 3 trial from the global REIMAGINE clinical trial program. CagriSema for weight management was submitted to the U.S. Food and Drug Administration (FDA) in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials. Trial Data REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination…See the Story

Blindspots

Health Insurance Companies Are Facing a Major Financial Gap – What This Means for Insured Persons

Breaking News Topics Related to Deutsches Ärzteblatt